Dacomitinib Nitroso
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds. Dacomitinib is used to treat non-small cell lung cancer that has spread (metastatic) with an epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutation gene. Your doctor will use a test to check for the mutation before you receive this medicine.Dacomitinib Nitroso is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Dacomitinib Nitroso CAS NO:NA chemically represented as (E)-N-(4-((3-Chloro-4-fluorophenyl)(nitroso)amino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide . Synchemia is the leading manufacturing and exporter of Dacomitinib Nitroso . We supply Dacomitinib Nitroso with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0143525 |
| CAS No | NA |
| Mol.F. | C15H18N4O4 |
| Mol.Wt. | 318.33 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143526 |
| CAS No | NA |
| Mol.F. | C14H16N4O3 |
| Mol.Wt. | 288.31 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143527 |
| CAS No | NA |
| Mol.F. | C15H18N4O4 |
| Mol.Wt. | 318.33 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143528 |
| CAS No | NA |
| Mol.F. | C12H15N3O4 |
| Mol.Wt. | 265.27 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143529 |
| CAS No | NA |
| Mol.F. | C7H8ClN3O3 |
| Mol.Wt. | 217.61 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143530 |
| CAS No | NA |
| Mol.F. | C15H18N4O3 |
| Mol.Wt. | 302.33 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143531 |
| CAS No | NA |
| Mol.F. | C15H20N4O3 |
| Mol.Wt. | 304.35 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143531 |
| CAS No | NA |
| Mol.F. | C15H20N4O3 |
| Mol.Wt. | 304.35 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143532 |
| CAS No | NA |
| Mol.F. | C15H19ClN4O2 |
| Mol.Wt. | 322.79 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143533 |
| CAS No | NA |
| Mol.F. | C15H19ClN4O2 |
| Mol.Wt. | 322.79 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143534 |
| CAS No | NA |
| Mol.F. | C23H29N5O2 |
| Mol.Wt. | 407.52 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143535 |
| CAS No | NA |
| Mol.F. | C15H17ClN4O2 |
| Mol.Wt. | 320.78 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143536 |
| CAS No | NA |
| Mol.F. | C23H27N5O2 |
| Mol.Wt. | 405.50 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143537 |
| CAS No | NA |
| Mol.F. | C23H27N5O2 |
| Mol.Wt. | 405.50 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143538 |
| CAS No | NA |
| Mol.F. | C15H18N4O4 |
| Mol.Wt. | 318.33 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143539 |
| CAS No | NA |
| Mol.F. | C15H18N4O4 |
| Mol.Wt. | 318.33 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |